# US 6,727,245 B2 · Heterobicyclic derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,245 B2
- Document ID: US6727245B2
- Status: Granted
- Kind: B2
- Application number: 10/050,855
- Filed: 2002-01-18
- Published: 2002-08-08
- Granted: 2004-04-27
- Earliest claimed: 1994-07-11
- Assignees: Fujisawa Pharmaceutical Co., Ltd.
- Inventors: Norihiko Shimazaki; Shinya Watanabe; Akihiko Sawada; Keiji Hemmi
- Web page: https://patentgrep.com/patent/US6727245B2

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 11/06: Antiasthmatics
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Heterobicyclic derivatives of the formula: wherein R1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R2 is aryl which may have suitable substituent(s) or heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.

## Claims

### Claim 1

A method for treating a disease or disorder mediated by phosphodiesterase IV (PDE-IV), tumor necrosis factor (TNF), or both, comprising administering an effective amount of a compound of formula (I) to a subject in need thereof, wherein the compound of formula (I) is:
wherein R1 is
aryl which may have one or more suitable substituent(s),
ar(lower)alkyl which may have one or more suitable substituent(s),
halo(lower)alkyl,
carboxyethyl,
protected carboxy(lower)alkyl,
acyl(lower)alkyl,
a heterocyclic group which may have one or more suitable substituent(s) or
a heterocyclic(lower)alkyl group which may have one or more suitable substituent(s);
R2 is aryl which may have one or more suitable substituent(s) or a heterocyclic group, and
R3 is hydrogen, lower alkoxy or arylthio,
or a pharmaceutically acceptable salt thereof;
provided that when R1 is phenyl, halophenyl, trihalo(lower)alkyl, carboxyethyl, piperidyl, morpholinyl, piperazinyl, or alkylpiperazinyl, then R2 is not substituted phenyl, piperidyl, morpholinyl, piperazinyl, or alkylpiperazinyl, and wherein the disease or disorder is selected from the group consisting of, osteoporosis, transplantation rejection, asthma, eosinophilia, cystic fibrosis, hepatitis, pancreatitis, nephritis, endotoxic shock, ankylosing spondylitis, an autoimmune hematological disorder, polychondritis, scleroderma, Wegener granulamotosis, dermatomyositis, chronic active hepatitis, atopic dermatitis, psoriasis, idiopathic sprue, autoimmune inflammatory bowel disease, endocrine ophthalmopathy, Grave's disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), Reiter's syndrome, non infection uveitis, autoimmune keratitis, interstitial lung fibrosis, psoriatic arthritis, cancer cachexia, AIDS cachexia, and thrombosis.

### Claim 2

A method for treating hepatitis comprising:
administering an effective amount of the compound of formula (I) to a subject in need thereof,
wherein the compound of formula (I) is:
wherein R1 is
aryl which may have one or more suitable substituent(s),
ar(lower)alkyl which may have one or more suitable substituent(s),
halo(lower)alkyl,
carboxyethyl,
protected carboxy(lower)alkyl,
acyl(lower)alkyl,
a heterocyclic group which may have one or more suitable substituent(s) or
a heterocyclic(lower)alkyl group which may have one or more suitable substituent(s);
R2 is aryl which may have one or more suitable substituent(s) or a heterocyclic group, and
R3 is hydrogen, lower alkoxy or arylthio,
or a pharmaceutically acceptable salt thereof;
provided that when R1 is phenyl, halophenyl, trihalo(lower)alkyl, carboxyethyl, piperidyl, morpholinyl, piperazinyl, or alkylpiperazinyl, then R2 is not substituted phenyl, piperidyl, morpholinyl, piperazinyl, or alkylpiperazinyl.

### Claim 3 (depends on 2)

The method of claim 2 comprising treating a human subject.
